Cleveland Clinic, The

Cleveland, Ohio 44195

0 studies enrolling now · 9 studies all time

What they study most

Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Anaplastic Large-Cell Lymphoma, DLBCL, Diffuse Large B-cell Lymphoma, Disease, Hodgkin, Fallopian Tube Cancer, Grade 3 Follicular Lymphoma, Hodgkin Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Studies at this site

• A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression — Completed
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma — Stopped early
• A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) — Completed
• ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas — Completed
• A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) — Completed
• A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma — Stopped early
• A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML — Completed
• A Safety Study of SGN-CD33A in AML Patients — Completed
• A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma — Completed